Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sathornsumetee, Sith, Desjardins, Annick, Vredenburgh, James J., McLendon, Roger E., Marcello, Jennifer, Herndon, James E., Mathe, Alyssa, Hamilton, Marta, Rich, Jeremy N., Norfleet, Julie A., Gururangan, Sridharan, Friedman, Henry S., Reardon, David A.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2010
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018944/
https://ncbi.nlm.nih.gov/pubmed/20716591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq099
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items